| Breast cancer genomics and immuno-oncological markers to guide immune therapies D Hammerl, M Smid, AM Timmermans, S Sleijfer, JWM Martens, R Debets Seminars in cancer biology 52, 178-188, 2018 | 172 | 2018 |
| Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer D Hammerl, JWM Martens, M Timmermans, M Smid, AM Trapman-Jansen, ... Nature communications 12 (1), 5668, 2021 | 156 | 2021 |
| Adoptive T cell therapy: new avenues leading to safe targets and powerful allies D Hammerl, D Rieder, JWM Martens, Z Trajanoski, R Debets Trends in immunology 39 (11), 921-936, 2018 | 48 | 2018 |
| Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes D Hammerl, MPG Massink, M Smid, CHM van Deurzen, ... Clinical Cancer Research 26 (2), 505-517, 2020 | 39 | 2020 |
| Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes? MC Agahozo, D Hammerl, R Debets, M Kok, CHM van Deurzen Modern Pathology 31 (7), 1012-1025, 2018 | 34 | 2018 |
| Association of microRNA-7 and its binding partner CDR1-AS with the prognosis and prediction of 1st-line tamoxifen therapy in breast cancer K Uhr, AM Sieuwerts, V de Weerd, M Smid, D Hammerl, JA Foekens, ... Scientific Reports 8 (1), 9657, 2018 | 33 | 2018 |
| V-domain Ig suppressor of T cell activation (VISTA) expression is an independent prognostic factor in multiple myeloma P Mutsaers, HE Balcioglu, R Kuiper, D Hammerl, R Wijers, M van Duin, ... Cancers 13 (9), 2219, 2021 | 13 | 2021 |
| Cancer germline antigens and tumor-agnostic CD8+ T cell evasion D Kortleve, RML Coelho, D Hammerl, R Debets Trends in Immunology 43 (5), 391-403, 2022 | 11 | 2022 |
| TME-analyzer: a new interactive and dynamic image analysis tool that identified immune cell distances as predictors for survival of triple negative breast cancer patients HE Balcioglu, R Wijers, M Smid, D Hammerl, AM Trapman-Jansen, ... npj Imaging 2 (1), 21, 2024 | 3 | 2024 |
| Gene engineering T cells with T-cell receptor for adoptive therapy D Kortleve, M van Brakel, R Wijers, R Debets, D Hammerl Immunogenetics: Methods and Protocols, 209-229, 2022 | 2 | 2022 |
| Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells MC Agahozo, M Smid, R van Marion, D Hammerl, TPP van den Bosch, ... Biology 10 (8), 768, 2021 | 2 | 2021 |
| TCR-engineered T cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer D Kortleve, D Hammerl, M van Brakel, R Wijers, D Roelofs, K Kroese, ... Cancer discovery 14 (12), 2450-2470, 2024 | 1 | 2024 |
| Detection of low-frequency epitope-specific T cells in blood of healthy individuals according to an optimized in vitro amplification system S Mahajan, D Kortleve, R Debets, D Hammerl The Journal of Immunology 209 (11), 2239-2247, 2022 | 1 | 2022 |
| 64P Gene-editing of T cells to provide resistance against macrophage-mediated suppression: Setting up an in vitro model R Coelho, C Schliehe, E Shifrut, R Debets, D Hammerl Immuno-Oncology and Technology 24, 2024 | | 2024 |
| 381 Co-stimulatory T cell receptors equipped with ICOS mediate durable anti-tumor activity APL Marraffa, C Berrevoets, M Mosiello, R Wijers, K Kroese, D Roelofs, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 2), 2024 | | 2024 |
| 1105 PCT1: co-stim TCR T-cells to target triple-negative breast cancer and overcome its hostile micro-environment D Hammerl, D Kortleve, APL Marraffa, M Van Brakel, R Wijers, D Roelofs, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 2), 2024 | | 2024 |
| 361 T cell receptor specific for tumor-restricted Ropporin-1 to treat triple negative breast cancer D Hammerl, D Kortleve, M Van Brakel, R Wijers, D Roelofs, M Badoux, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Innovative platforms for development of TCR-T cell therapies against novel tumor targets: Triple negative breast cancer. RJM Abbott, D Hammerl, D Kortleve, M van Brakel, R Wijers, D Roelofs, ... Journal of Clinical Oncology 41 (16_suppl), e14536-e14536, 2023 | | 2023 |
| Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells. Biology 2021, 10, 768 MC Agahozo, M Smid, R van Marion, D Hammerl, TPP van den Bosch, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | | 2021 |
| Immunity in Breast Cancer: Charting T cell evasion and exploring new targets for T cells D Hammerl | | 2020 |
